The UK company’s new partner will distribute the cholesterol-reducing probiotic, LPLDL, both as an ingredient and as four finished products – CholBiome, CholBiomeX3, CholBiomeBP and CholBiome.
OptiBiotix said the deal offered an “agreed and expected” first order within 30 days from approval by the Brazilian authorities of its food technology.
The agreement is for an initial 12 months and there are “modest minimum order quantities for each product providing the company security of income and revenue growth”, investors were told.
“We chose Ayalla because of its reputation and expertise in commercialising pharmaceutical and non-drug products with strong science and clinical studies in the Brazilian market,” Mikkel Hvid-Hansen, commercial director of ProBiotix Health said in a statement.
Founded in 1973, Ayalla started out providing active ingredients to the pharmaceutical industry. Its portfolio now covers the veterinary, food, cosmetics and fragrance industries.